<div>
 Thank you so much for taking the time to read our story. I’m writing this as a mum from the West Midlands, U.K., trying to do the impossible - save our child’s life.
</div>
<div>
 <br>
</div>
<div>
 Our son, Partaap Singh, is our brave, bright, confident 6 year old who lights up every room he walks into. He makes friends effortlessly with his sunny nature and beautiful smile, and he is always the first to help anyone who needs it. He is the most wonderful big brother to his younger brother, and is always looking out for him.
</div>
<div>
 <br>
</div>
<div>
 Early last year, we noticed small things that didn’t feel right. He began struggling to walk long distances, to stand up from sitting, and to climb stairs. He fell often, for no clear reason. What followed were months of hospital visits, tests, and endless worry. Through it all, Partaap was courageous, patient, and unbelievably strong.
</div>
<div>
 <br>
</div>
<div>
 In January, our world shattered. His genetic tests came back, and we were told he has an extremely rare, terminal, neurodegenerative disease called Juvenile ALS (amyotrophic lateral sclerosis), also known as MND (motor neuron disease). The gene variant causing his illness, SPTLC2, is so rare that only 40–50 children worldwide are believed to have it. No one knows how quickly it will progress in him, or how much time we have left. As parents, hearing this felt like the ground disappeared beneath us.
</div>
<div>
 <br>
</div>
<div>
 There is no cure for ALS. It destroys motor neurons in the brain and spinal cord, slowly taking away the ability to walk, move, speak, swallow, and eventually breathe. In adults, ALS is usually diagnosed around age 55+, and even then, most survive only 2–5 years. In children, it is so rare that very little is known and there are no clinical trials for Partaap’s gene variant.
</div>
<div>
 <br>
</div>
<div>
 Right now, Partaap struggles to walk more than a few minutes, to climb stairs, to balance, and to stand up from sitting. He falls often and his limbs are weak. But he is still fiercely independent. He still insists on walking wherever he can. He still plays football and tag with his younger brother. He still smiles.
</div>
<div>
 <br>
</div>
<div>
 And we refuse to give up.
</div>
<div>
 <br>
</div>
<div>
 <strong>Our Fight</strong>
</div>
<div>
 When doctors told us there was no cure, no treatment, and that we should focus on palliative care, we simply couldn’t accept that. Not for our child. Not without trying everything. That’s when we turned to clinical research where new therapies come to light.
</div>
<div>
 <br>
</div>
<div>
 One of the most promising approaches for rare genetic diseases is antisense oligonucleotides (ASOs), targeted treatments that can reduce harmful proteins or “switch off” faulty gene messages. In Partaap’s case, his gene variant causes an overproduction of sphingolipids, which is driving the disease.
</div>
<div>
 <br>
</div>
<div>
 An ASO for SPTLC2 related ALS has never been attempted before. But we are assembling a team to try to create a bespoke ASO for Partaap that could slow or even stop the progression of this devastating disease.
</div>
<div>
 <br>
</div>
<div>
 We are working with Jeff Milton, a scientist and biotechnology entrepreneur who has dedicated his career to making precision medicines accessible for people with rare neurodegenerative diseases. Jeff has worked at Arcturus Therapeutics, Ionis Pharmaceuticals, and Genentech, and now leads Baja Bio, developing individualized RNA targeted therapeutics. His work includes GBFsen, an individualized ASO for ALS, and ALS BAJAi, a serum biomarker for ALS diagnosis.
</div>
<div>
 <br>
</div>
<div>
 Jeff is helping us build a team for Partaap, but speed is everything. Every month that passes, we risk losing more of our son’s abilities.
</div>
<div>
 <br>
</div>
<div>
 <strong>Why We Need Your Help</strong>
</div>
<div>
 Because this disease is so rare, no one knows how aggressive it will be. To move quickly, we need to raise around £1 million to cover the costs of designing, developing, and delivering a potential ASO treatment - something that has never been done before for this gene.
</div>
<div>
 <br>
</div>
<div>
 Even if successful, ASOs are not a one time cure. They must be administered repeatedly every few months, meaning long term financial challenges.
</div>
<div>
 <br>
</div>
<div>
 On top of this, we face ongoing care costs: therapies, specialised equipment, home adaptations, travel, and everything needed to keep Partaap safe, comfortable, and able to enjoy his childhood.
</div>
<div>
 <br>
</div>
<div>
 We are giving everything we have, but we cannot do this alone.
</div>
<div>
 <br>
</div>
<div>
 Every donation, every share, every bit of support means the world to us.
</div>
<div>
 <br>
</div>
<div>
 Time is absolutely critical. Please help us fight for our son’s life, and help us turn his story into one of hope, courage, and possibility.
</div>
<div>
 <br>
</div>
<div>
 From our family to yours, thank you with all our hearts.
</div>
<div>
 <br>
</div>

Rajinder Kaur

Anonymous

Nirmal Bahara

Gurdeep Dhanjal

Sunita Virdee

Amarpreet Kaur

Gurpreet Dhaliwal

DALJIT JOHAL

Angela Ahir

Dabs Gill

Arsha Rani

Herbinder Upple

Anmol Vig

Race against time to save our 6 year old son, Partaap Singh

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

be_supporter_comments_enabled_supported_funds

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Race against time to save our 6 year old son, Partaap Singh

Still £964,550 to go. Help us build momentum.